References
1. Mahabadi, N. et al. NCBI [Online]. www.ncbi.nlm.nih.gov [Cited 7 March 2024]. Open Angle Glaucoma. From: https://www.ncbi.nlm.nih.gov/books/NBK441887/ [Accessed 30 September 2024].
2. Kaleem M. Johns Hopkins Medicine [Online]. www.hopkinsmedicine.org Glaucoma. From: https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma [Accessed 14 September 2024].
3. Álvarez-Sabín, J. and Roman, GC. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci. 2013;3:1395-1414. Available from DOI: 10.3390/brainsci3031395.
4. CEBROLUX™ NF professional information, April 2021.
5. Rossetti L., et al. The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial. Graefe’s Archive for Clinical and Experimental Ophthalmology (2023) 261:1659-1668. Available from DOI: https://doi.org/10.1007/s00417-022-05947-5.
6. Ottobelli L, et al. Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression? Ophthalmologica. 2013;229(4):219-226.
7. Rejdak R, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit. 2003;9(3):PI24-8.
8. Lanza M, Gironi Carnevale UA, Mele L, Bifani Sconocchia M, Bartollino S, Costagliola C. Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: A pilot study with a 2-year follow-up. Front Pharmacol. 2019;10:1117.
9. Cognizin®, Kyowa Hakko USA. [Online]. www.cognizin.com The Science of Citicoline. From: https://cognizin.com/en/science-of-citicoline [Accessed 30 September 2024].
10. Cognizin®, Kyowa Hakko USA. [Online]. www.cognizin.com FACTS FOR HEALTH PROFESSIONALS ABOUT COGNIZIN® CITICOLINE*. From: https://cognizin.com/en/healthcare-practitioners [Accessed 30 September 2024].
2. Kaleem M. Johns Hopkins Medicine [Online]. www.hopkinsmedicine.org Glaucoma. From: https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma [Accessed 14 September 2024].
3. Álvarez-Sabín, J. and Roman, GC. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci. 2013;3:1395-1414. Available from DOI: 10.3390/brainsci3031395.
4. CEBROLUX™ NF professional information, April 2021.
5. Rossetti L., et al. The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial. Graefe’s Archive for Clinical and Experimental Ophthalmology (2023) 261:1659-1668. Available from DOI: https://doi.org/10.1007/s00417-022-05947-5.
6. Ottobelli L, et al. Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression? Ophthalmologica. 2013;229(4):219-226.
7. Rejdak R, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit. 2003;9(3):PI24-8.
8. Lanza M, Gironi Carnevale UA, Mele L, Bifani Sconocchia M, Bartollino S, Costagliola C. Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: A pilot study with a 2-year follow-up. Front Pharmacol. 2019;10:1117.
9. Cognizin®, Kyowa Hakko USA. [Online]. www.cognizin.com The Science of Citicoline. From: https://cognizin.com/en/science-of-citicoline [Accessed 30 September 2024].
10. Cognizin®, Kyowa Hakko USA. [Online]. www.cognizin.com FACTS FOR HEALTH PROFESSIONALS ABOUT COGNIZIN® CITICOLINE*. From: https://cognizin.com/en/healthcare-practitioners [Accessed 30 September 2024].
S0 Proprietary name and dosage form: CEBROLUX™ NF powder for oral solution. Composition: Each 3g sachet contains: Citicoline (Cognizin®) 250 mg, Vitamin C 60 mg, Vitamin B3 12 mg, Vitamin E 8,2 mg, Zinc 6,25 mg, Vitamin B5 4,5 mg, Vitamin B6 1,05 mg, Vitamin B2 1,05 mg, Vitamin B1 0,83 mg, Vitamin A 600 μg, Folic acid 150 μg, Biotin 37,5 μg and Vitamin B12 1,875 μg. Complementary Medicine: Health Supplement.
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. For full prescribing information, refer to the Professional Information. Further information is available on request from Bausch + Lomb.
© 2024 Bausch & Lomb Incorporated or its affiliates. ®/™ denote trademarks of Bausch & Lomb Incorporated or its affiliates. COGNIZIN® is a registered trademark of KYOWA HAKKO BIO CO., LTD.
Distributed by: Soflens (Pty) Ltd. Reg. No.: 1968/011787/07. 254 Hall Street, Centurion, 0157. Tel: +27 10 025 2100. www.bausch.co.za BL714/24
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. For full prescribing information, refer to the Professional Information. Further information is available on request from Bausch + Lomb.
© 2024 Bausch & Lomb Incorporated or its affiliates. ®/™ denote trademarks of Bausch & Lomb Incorporated or its affiliates. COGNIZIN® is a registered trademark of KYOWA HAKKO BIO CO., LTD.
Distributed by: Soflens (Pty) Ltd. Reg. No.: 1968/011787/07. 254 Hall Street, Centurion, 0157. Tel: +27 10 025 2100. www.bausch.co.za BL714/24
